Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 20 February 2013 | By Louise Zornoza,
China's State Food and Drug Administration (SFDA) has announced the release of the revised pharmaceutical Good Supply (Distribution) Practices (GSP) slated to take effect on 1 June 1 2013, with a three-year transition period for the implementation by companies of the mandated quality control system.
Drug makers who fail to meet the amended GSP standards by 2016 will not be allowed to continue operations, regulators said.
This is the first major revision of the GSPs in more than a decade, and according to SFDA the revisions draw on those of the "World Health Organization (WHO), and the regulatory policies of the United States, the European Union and other developed countries and regions."
The revisions include the obligation to implement a quality control system with an electronic drug monitoring system, bar codes to ensure pharmaceutical traceability, use of standardized documentation and information technology, and ensuring that responsible persons are properly qualified.
A draft version of the revised GSPs was made available for comment on 25 April 2012.
Read all Breaking News from RegLink
Tags: GDP, SFDA